There are 2789 resources available
847P - The utility of serum amylase as a clinical marker in patients with multiple myeloma
Presenter: Chetana Panthula
Session: ePoster Display
Resources:
Abstract
849P - Demographics of Langerhans cell histiocytosis patients who died during the 2010-2017
Presenter: Sai Giridhar Gundepalli
Session: ePoster Display
850P - Acute lymphoblastic leukemia patients receiving prophylactic cranial irradiation by volumetric modulated ARC therapy with hippocampal sparing: Dosimetric analysis
Presenter: Ambedkar Yadala
Session: ePoster Display
851P - Treatment efficacy for adults with relapsed or refractory acute lymphoblastic leukemia: A systematic literature review (SLR)
Presenter: Yun Liu
Session: ePoster Display
733P - Bevacizumab (Bev), olaparib (Ola) and durvalumab (Durva) in patients with recurrent advanced ovarian cancer (AOC): The GINECO BOLD study
Presenter: Gilles Freyer
Session: ePoster Display
734P - Neutrophil-lymphocyte ratio predicts survival in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD): Stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601
Presenter: Jose Alejandro Perez Fidalgo
Session: ePoster Display
736P - Preliminary results of anlotinib and niraparib dual therapy evaluation in platinum-resistant recurrent ovarian cancer (ANNIE): A multicenter, single-arm, phase II trial
Presenter: jihong Liu
Session: ePoster Display
737P - Phase II study of IV vinorelbine in relapsed platinum resistant or refractory C5 high grade serous primary peritoneal, fallopian tube or ovarian cancer (VIP)
Presenter: Natalie Ngoi
Session: ePoster Display
738P - Quality-adjusted time without symptom or toxicity (QA-TWiST) and quality-adjusted progression-free survival (QA-PFS) of first-line (1L) maintenance niraparib in patients with advanced ovarian cancer (OC): Results from the PRIMA trial
Presenter: Maria-Pilar Barretina-Ginesta
Session: ePoster Display